Lilly halts enrollment in brain-cancer trial

Share this article:
Following the report of an external monitoring committee, Eli Lilly decided to halt enrollment in a late-stage clinical trial for cancer agent enzastaurin. Just two weeks ago, the company had told investors and analysts it was forging ahead with a phase III trial studying the compound in recurrent glioblastoma, an aggressive form of brain cancer. The trial was stopped after the committee’s report suggested enzastaurin would not improve progression-free survival over existing chemotherapy. Other enzastaurin trials are unaffected by the report, however. Lilly is enrolling patients in a Phase III trial testing enzastaurin for use as a maintenance therapy for the treatment of non-Hodgkin’s lymphoma. And several phase II studies continue across a variety of more common tumor types, including breast, colon, lung, ovarian and prostate cancers. Although the report was a minor setback, analysts called it the latest sign of softness in Lilly’s pipeline. In August, the FDA failed to approve diabetic retinopathy drug Arxxant (ruboxistaurin), subsequently asking for an additional phase III clinical trial which could take up to five years to complete. Lilly is appealing that decision. And last year Lilly said it was delaying development of anti-clotting drug called Prasugrel. Analysts had expected it to be on the market in 2007. Lilly said it expects to submit Prasugrel for FDA approval late next year.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...